Editorial: Targeting Bruton Tyrosine Kinase.
作者信息
Brunner Cornelia, Betzler Annika C, Brown Jennifer R, Andreotti Amy H, Grassilli Emanuela
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
出版信息
Front Cell Dev Biol. 2022 Apr 26;10:909655. doi: 10.3389/fcell.2022.909655. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Targeting Bruton Tyrosine Kinase.社论：靶向布鲁顿酪氨酸激酶
Front Cell Dev Biol. 2022 Apr 26;10:909655. doi: 10.3389/fcell.2022.909655. eCollection 2022.
2
Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.人 NACHT、LRR 和 PYD 结构域包含蛋白 3（NLRP3）炎症小体的活性受布鲁顿酪氨酸激酶调节，并且可能成为其作用靶点。
J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10. doi: 10.1016/j.jaci.2017.01.017. Epub 2017 Feb 16.
3
Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.抑制布鲁顿酪氨酸激酶作为多发性硬化症的一种新的治疗方法。
Expert Opin Investig Drugs. 2020 Oct;29(10):1143-1150. doi: 10.1080/13543784.2020.1807934. Epub 2020 Aug 19.
4
Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors.天疱疮中的转化性自身免疫及新型布鲁顿酪氨酸激酶抑制剂的作用
J Transl Autoimmun. 2022 Apr 16;5:100156. doi: 10.1016/j.jtauto.2022.100156. eCollection 2022.
5
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.依鲁替尼抑制布鲁顿蛋白酪氨酸激酶（BTK）在B细胞肿瘤治疗中的应用。
Pharmacol Res. 2016 Nov;113(Pt A):395-408. doi: 10.1016/j.phrs.2016.09.011. Epub 2016 Sep 15.
6
Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage.阿卡替尼对布鲁顿酪氨酸激酶的抑制作用可减轻脂多糖/半乳糖胺诱导的肝损伤。
Biomed Pharmacother. 2020 Nov;131:110736. doi: 10.1016/j.biopha.2020.110736. Epub 2020 Sep 17.
7
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.布鲁顿酪氨酸激酶抑制剂 PCI-32765 可阻断 B 细胞激活，并在自身免疫性疾病和 B 细胞恶性肿瘤模型中有效。
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.
8
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.布鲁顿酪氨酸激酶（BTK）及其在 B 细胞恶性肿瘤中的作用。
Int Rev Immunol. 2012 Apr;31(2):119-32. doi: 10.3109/08830185.2012.664797.
9
Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.小分子布鲁顿酪氨酸激酶（BTK）抑制剂作为一种有前途的癌症治疗方法的研究进展。
Bioorg Med Chem. 2021 Oct 1;47:116358. doi: 10.1016/j.bmc.2021.116358. Epub 2021 Aug 10.
10
Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.布鲁顿酪氨酸激酶抑制作用及其作为天疱疮新兴治疗方法的作用
Front Med (Lausanne). 2021 Aug 10;8:708071. doi: 10.3389/fmed.2021.708071. eCollection 2021.
引用本文的文献
1
Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.布鲁顿酪氨酸激酶抑制剂（BTKIs）：临床前研究综述与临床试验评估。
Molecules. 2023 Mar 6;28(5):2400. doi: 10.3390/molecules28052400.
本文引用的文献
1
The role of Bruton's tyrosine kinase in the immune system and disease.布鲁顿酪氨酸激酶在免疫系统和疾病中的作用。
Immunology. 2021 Dec;164(4):722-736. doi: 10.1111/imm.13416. Epub 2021 Oct 4.
2
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.p65BTK 是 KRAS 突变/EGFR 野生型肺腺癌的一个新的潜在可操作靶点。
J Exp Clin Cancer Res. 2019 Jun 14;38(1):260. doi: 10.1186/s13046-019-1199-7.
3
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.一种新的布鲁顿酪氨酸激酶异构体（p65BTK）在胶质母细胞瘤肥胖细胞组织学类型中的特异性表达。
Front Mol Neurosci. 2019 Jan 24;12:2. doi: 10.3389/fnmol.2019.00002. eCollection 2019.
4
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.伊布替尼，一种布鲁顿酪氨酸激酶抑制剂，在胶质母细胞瘤中表现出抗肿瘤活性并诱导自噬。
J Exp Clin Cancer Res. 2017 Jul 17;36(1):96. doi: 10.1186/s13046-017-0549-6.
5
Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.人 NACHT、LRR 和 PYD 结构域包含蛋白 3（NLRP3）炎症小体的活性受布鲁顿酪氨酸激酶调节，并且可能成为其作用靶点。
J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10. doi: 10.1016/j.jaci.2017.01.017. Epub 2017 Feb 16.
6
Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth.使用依鲁替尼靶向布鲁顿酪氨酸激酶（Btk）可抑制胃癌细胞的生长。
Am J Transl Res. 2016 Jul 15;8(7):3003-12. eCollection 2016.
7
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.一种新型致癌性BTK异构体在结肠癌中过表达，且是RAS介导的细胞转化所必需的。
Oncogene. 2016 Aug 18;35(33):4368-78. doi: 10.1038/onc.2015.504. Epub 2016 Jan 25.
8
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.布鲁顿酪氨酸激酶是前列腺癌的一个潜在治疗靶点。
Cancer Biol Ther. 2015;16(11):1604-15. doi: 10.1080/15384047.2015.1078023. Epub 2015 Sep 18.
9
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.B细胞受体信号传导及其在正常细胞和恶性细胞中与其他信号通路的相互作用。
Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13.
10
A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.一种新型 B 细胞酪氨酸激酶 BTK 异构体可保护乳腺癌细胞免于凋亡。
Genes Chromosomes Cancer. 2013 Oct;52(10):961-75. doi: 10.1002/gcc.22091. Epub 2013 Aug 3.
Zotero 插件